Tarsus Pharmaceuticals (TARS) Net Cash Flow Growth (3y) (2022 - 2026)
Tarsus Pharmaceuticals (TARS) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.12 Bn | 466.33 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 121.84 Bn | 114.59 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.89 Bn | 61.14 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.64 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.34 Bn | 34.34 Bn | 959.66 Mn | 32.17% |
| 10 | Tarsus Pharmaceuticals | 2.61 Bn | 2.50 Bn | 152.66 Mn | -143.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -143.75% |
| Dec 31, 2025 | 39.67% |
| Sep 30, 2025 | 30.29% |
| Jun 30, 2025 | -46.20% |
| Mar 31, 2025 | 180.27% |
| Dec 31, 2024 | -84.91% |
| Sep 30, 2024 | -39.10% |
| Jun 30, 2024 | -37.75% |
| Mar 31, 2024 | -37.76% |
| Dec 31, 2023 | -26.43% |
| Sep 30, 2023 | 53.43% |
| Jun 30, 2023 | 156.04% |
| Mar 31, 2023 | -40.11% |
| Dec 31, 2022 | -54.64% |